Market revenue in 2023 | USD 301.7 million |
Market revenue in 2030 | USD 578.5 million |
Growth rate | 9.7% (CAGR from 2023 to 2030) |
Largest segment | Outpatient facilities |
Fastest growing segment | Research & Manufacturing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Hospitals, Outpatient Facilities, Research & Manufacturing |
Key market players worldwide | GE HealthCare Technologies Inc Common Stock, Abbott Laboratories, Roche Holding AG, Qiagen NV, Becton Dickinson & Co, Siemens Healthineers AG ADR, Thermo Fisher Scientific Inc, Hologic Inc, Koninklijke Philips NV, Illumina Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to blood cancer diagnostics market will help companies and investors design strategic landscapes.
Outpatient facilities was the largest segment with a revenue share of 68.08% in 2023. Horizon Databook has segmented the South Korea blood cancer diagnostics market based on hospitals, outpatient facilities, research & manufacturing covering the revenue growth of each sub-segment from 2018 to 2030.
South Korea blood diagnostics market has experienced significant growth over recent years, driven by several key factors. The country's rapidly aging population has led to a surge in demand for accurate and timely diagnostic tests, particularly for chronic diseases such as blood cancer.
In addition, the increasing prevalence of blood cancer has fueled the need for advanced diagnostic technologies to detect and monitor the disease. Furthermore, the government's efforts to promote healthcare innovation and investment in biotechnology have created a favorable environment for companies to develop and commercialize new diagnostic products & services.
As a result, South Korea is becoming an appealing hub for international players in the diagnostics industry, with many multinational companies establishing operations or partnering with local firms to tap into the market's growth potential.
Horizon Databook provides a detailed overview of country-level data and insights on the South Korea blood cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into South Korea blood cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account